Pharmacologically targeted NMDA receptor antagonism by NitroMemantine for cerebrovascular disease

Hiroto Takahashi1,*, Peng Xia1,*, Jiankun Cui1,*, Maria Talantova1,†, Karthik Bodhinathan1, Wenjun Li1, Sofiyan Saleem1, Emily A. Holland1,†, Gary Tong1,†, Juan Piña-Crespo1, Dongxian Zhang1, Nobuki Nakanishi1,†, James W. Larrick2, Scott R. McKercher1,†, Tomohiro Nakamura1,†, Yuqiang Wang3 & Stuart A. Lipton1,4,†

Stroke and vascular dementia are leading causes of morbidity and mortality. Neuroprotective therapies have been proposed but none have proven clinically tolerated and effective. While overstimulation of N-methyl-D-aspartate-type glutamate receptors (NMDARs) is thought to contribute to cerebrovascular insults, the importance of NMDARs in physiological function has made this target, at least in the view of many in ‘Big Pharma,’ ‘undruggable’ for this indication. Here, we describe novel NitroMemantine drugs, comprising an adamantane moiety that binds in the NMDAR-associated ion channel that is used to target a nitro group to redox-mediated regulatory sites on the receptor. The NitroMemantines are both well tolerated and effective against cerebral infarction in rodent models via a dual allosteric mechanism of open-channel block and NO/redox modulation of the receptor. Targeted S-nitrosylation of NMDARs by NitroMemantine is potentiated by hypoxia and thereby directed at ischemic neurons. Allosteric approaches to tune NMDAR activity may hold therapeutic potential for cerebrovascular disorders.

Focal cerebral ischemia (stroke) and vascular dementia (due to multiple strokes in the microvasculature) represent leading causes of severe cognitive dysfunction and death worldwide1. While excessive stimulation of N-methyl-D-aspartate-type glutamate receptors (NMDARs) is acknowledged to be important in the etiology of cerebrovascular damage2,3, NMDAR antagonists were previously found to be either ineffective or clinically intolerable for cerebral ischemic insults in humans despite promising early results in animal models4–6. Many in ‘Big Pharma’ have thus made the tacit assumption that NMDARs are not ‘druggable’ for cerebrovascular insults. However, the possibility exists that rather than the target being intractable, the specific antagonists used were not adequately designed. Data presented here support the premise that the case for NMDAR antagonists should be revisited.

One important relatively new concept concerns the population of NMDARs that are excessively activated during cerebral ischemia and vascular dementia. Recent evidence supports the notion that under most conditions pathological activity is predominantly mediated by extrasynaptic NMDARs, whereas physiological synaptic NMDAR activity triggers neuroprotective molecular pathways in neurons7,8.

1Neuroscience and Aging Research Center, Sanford-Burnham-Prebys Medical Discovery Institute, La Jolla, California 92037, USA. 2Panorama Research, Inc., Sunnyvale, California 94089, USA. 3Institute of New Drug Research, Jinan University College of Pharmacy, Guangzhou 510632, China. 4Department of Neurosciences, University of California San Diego School of Medicine, La Jolla, California 92039, USA. *These authors contributed equally to this work. †Present address: Neurodegenerative Disease Center, Scintillon Institute, San Diego, CA 92121 (M.T., E.H., S.R.M., T.N., N.N., S.A.L.); Lundbeck, Inc., Deerfield, IL 60015 (G.T.). Correspondence and requests for materials should be addressed to S.A.L. (email: slipton@ucsd.edu)
One well-studied NMDAR antagonist in particular, memantine, represents an uncompetitive/fast off-rate ('UFO') drug, which primarily affects extrasynaptic/tonically-activated NMDARs over synaptic/phasically-activated NMDARs. In fact, memantine has shown promise not only in animal studies of stroke but also in a phase 2 human clinical trial for efficacy in vascular dementia. Nonetheless, despite its approval by the FDA and EMA for moderate-to-severe Alzheimer's disease, the drug has not been tested in additional advanced trials for ischemic disease because of its fairly modest effects. Here, we develop and characterize improved analogs of memantine, representing aminoadamantane nitrates that demonstrate both increased efficacy and safety in animal models of cerebral ischemia. Importantly, detailed demonstration of target selectivity, electrophysiological properties, and neurobehavioral effects of the lead candidate, designated YQW-036/NMI-6979 NitroMemantine, provide a promising therapeutic profile. Early pharmacokinetic studies also indicate that this drug may represent a viable candidate for diseases related to cerebral ischemia.

We show here that NitroMemantines offer an advantage over memantine, at least in part, because the new drugs manifest a dual site of action at the NMDAR; accordingly, NitroMemantine performs in a superior fashion to memantine in treatment of a rat model of focal cerebrovascular disease. The memantine moiety, which preferentially blocks excessively open NMDAR-operated channels in neurons undergoing ischemic insult, is used to target an NO-generating group to the redox modulatory sites of those NMDARs; these redox sites then undergo S-nitrosylation to cause channel desensitization, resulting in a dual action of the NitroMemantine drugs via channel blockade coupled to allosteric redox modulation. The results show that NitroMemantine offers significantly more protection than memantine against cerebral ischemic insults, while sparing a greater proportion of synaptic transmission. Perhaps most importantly, NitroMemantine is an example of an FDA-approved drug (memantine) that is used to target a second moiety to the same receptor in order to enhance efficacy of action. This principal may serve as a new platform for clinically-tolerated drug discovery in the CNS.

**Results**

**Open-channel block and redox effects of NitroMemantines.** We have previously shown that the NMDAR can be antagonized by memantine via open-channel block as well as by nitric oxide (NO)-based compounds via an allosteric redox-modulatory site(s) that is subject to S-nitrosylation. Moreover, we demonstrated that memantine preferentially interacts with excessively (pathologically) open NMDAR-associated channels. Additionally, during hypoxia, NO-based compounds preferentially react with allosteric cysteine residues in the NMDAR to limit excessive activity. In an effort to combine these attributes and produce a dual functional drug that targets the NO group to pathological-activating NMDARs, we have designed a series of drugs that utilize the bridgehead amine of nitroglycerin onto memantine (represented by compound YQW-035), we decreased the potency of steady-state channel block during electrophysiological recordings from frog oocytes expressing recombinant NMDARs (Fig. 1b). We found that by lengthening the side chains of memantine we could compensate for lost drug affinity in the channel associated with the addition of the –ONO₂ functional group of nitroglycerin onto memantine (represented by compound YQW-035), thereby improving the selectivity and efficacy of the new drug (Fig. 1c). We also observed that these new compounds, like memantine, display voltage-dependent inhibition of NMDA-evoked currents in recordings from rat cerebrocortical neurons, as expected for a positively-charged open-channel blocker (Fig. 1e). However, this property may partly account for the relatively weak clinical efficacy of memantine. When neurons become energetically compromised, and consequently depolarize because of the inrush of positively charged Na⁺ and Ca²⁺ ions, memantine is repelled from the ion channel. Thus, the ‘sickiest’ neurons, which need neuroprotection the most, become vulnerable.
In an attempt to remedy this shortcoming, the NitroMemantine adducts manifest a second, redox-based inhibition of NMDA-induced current. This additional allosteric site of action produces a relatively long-lasting inhibition of NMDARs resulting from S-nitrosylation that is mediated by the nitro group, as demonstrated in voltage-clamped oocyte recordings (Fig. 2a)\(^20,27,28\). Unlike channel block by the memantine moiety, this second allosteric effect requires several minutes of drug addition for onset of action (and therefore is not evident in the short-term additions in Fig. 1) and survives washout by many minutes\(^20,27,28\). To insure that NitroMemantine had not entered the channel during the washout period, as opposed to during subsequent agonist addition as expected of an open-channel blocker, we analyzed the rise times of the individual NMDA-evoked responses before and after YQW-036 addition; we found that rise times were similar (inset in Fig. 2c), as expected if the antagonist were not already residing in the channel, i.e., trapped, prior to agonist addition\(^10,29\). We can further distinguish the redox effect of the nitro group from the channel block of the aminoadamantane core in two additional ways.

First, the effect of S-nitrosylation is abrogated by systematic mutation of five cysteine residues (Fig. 2b).
Figure 2. Redox effects of NitroMemantine YQW-036 mediated by S-nitrosylation. (a) Representative recordings under two-electrode voltage clamp in oocytes expressing wild-type (WT) or non-nitrosylatable cysteine mutant NMDAR subunits. (b) Quantification of contribution of cysteine residues in various NMDAR subunits to the inhibitory effect of S-nitrosylation (data are mean ± s.e.m. for n ≥ 5 recordings per data point, **P < 0.01). (c) In oocyte recordings of NMDA-evoked currents under voltage clamp, inhibition by NitroMemantine (10 μM) largely occluded any additional effect of subsequent application of the sulfhydryl-reactive reagent MTSEA (0.5 mM), as expected if the same cysteine residues were involved. Inset: expanded time scale to show rise time of NMDA-evoked current before and after NitroMemantine addition. (d) Inhibition of NMDA-evoked currents by MTSEA occludes the redox-mediated inhibitory effect of subsequent addition of NitroMemantine. (e) Quantification of effects shown in c and d. Data are mean ± s.e.m. for n ≥ 6 oocytes recordings per data point (∗P < 0.005). (f) NitroMemantine inhibits NMDAR activity by S-nitrosylation. Addition of 100 μM NitroMemantine YQW-036, but not its metabolite memantine-OH, inhibited NMDA-evoked current in oocytes expressing GluN1/GluN2A NMDARs recorded under voltage clamp conditions used to observe S-nitrosylation (Va = −60 mV; data representative of n ≥ 4 oocytes recordings). (g) Mutation of the memantine binding site in the GluN1 subunit of the NMDAR prevents the redox effect of NitroMemantine. Disruption of the memantine binding site by mutation GluN1(N616R) abrogated the redox-mediated activity of NitroMemantine (100 μM). Data representative of n ≥ 3 oocytes recordings.
Importantly, prior work has shown that mutation of these same cysteine residues does not affect other properties of the NMDAR, including inhibition at the Mg\(^{2+}\) memantine binding site in the channel\(^{20,30}\). Note also that under ambient air conditions, as tested here, the majority of the effect is mediated by Cys399 on the GluN2A (previously designated NR2A) subunit. However, as previously demonstrated\(^{22}\), inhibition by the nitro group is markedly increased under hypoxic conditions relevant to stroke and vascular dementia; under these conditions, four other cysteine residues in GluN1 and GluN2 contribute to the S-nitrosylation effect. Second, S-nitrosylation, unlike channel block, can be prevented by prior incubation with a small molecule, sulphhydril-reactive agent like methanethiosulfonate ethylammonium (MTSEA), which reacts with the same cysteine residues and thus occludes the effect of the nitro group (Fig. 2c–e).

**Targeting the NO group to the NMDAR via the memantine moiety.** Memantine binding in the NMDAR-associated channel is largely abrogated by mutation at or near the Mg\(^{2+}\) site, e.g., in NMDARs with GluN1(N616R)/GluN2 subunit composition\(^{22,31}\). We tested the ability of the core aminoadamantane structure to target NO\(_2\) to the S-nitrosylation/redox sites external to the memantine-binding site in the channel by mutating the memantine binding site. Since mutation of the channel caused smaller currents than those of wild-type (WT) NMDARs, it was necessary in these experiments to use relatively high concentrations (e.g., 100\(\mu \)M) of NitroMemantine in order to increase the magnitude of the effect. We compared our lead NitroMemantine drug, YQW-036, to the 1-amino-3',5',5'-diethyl-7-hydroxy-adamantane scaffold without the nitro group (designated here as memantine-OH)\(^{18,19}\). We found that mutation of the memantine binding site largely abrogated the activity of NitroMemantines (Fig. 2f,g and Supplementary Fig. 2), whereas a high concentration of the NO donor S-nitroscysteine (SNOC) inhibited both the WT and mutant NMDARs (Supplementary Fig. 2). These results indicate that the aminoadamantane core moiety can target the nitro group to the receptor; mutation of the aminoadamantane binding site prevented this targeting.

To further confirm this targeting, we performed biotin switch assays to measure S-nitrosylated proteins following systemic administration of NitroMemantine YQW-036 in rats undergoing stroke. NitroMemantine, but not memantine, resulted in a significant increase in S-nitrosylation of the GluN1 subunit of the NMDAR (forming SNO-GluN1) in the cortical parenchyma ipsilateral but not contralateral to the stroke (Fig. 3). In contrast, S-nitrosylation of other proteins that we have shown to be aberrantly nitrosylated during neurodegeneration, e.g., dynamin related protein 1 (Drp1), were not significantly affected by NitroMemantine. This experiment shows pharmacodynamic targeting of the nitro group by NitroMemantine to NMDARs at the site of the pathophysiological insult.

**NitroMemantine relatively spares synaptic activity, long-term potentiation, and Morris water maze performance.** Most NMDAR antagonists produce neurobehavioral abnormalities by blocking normal neurotransmission; however, memantine does not exhibit these side effects\(^{8,11,12,32,33}\). Previously, we had tested memantine and NitroMemantine drugs on the rat hippocampal autapse preparation and on human induced pluripotent stem cell (hiPSC)-derived cortical neurons, and showed that they preferentially blocked extrasynaptic NMDAR-mediated responses, which contributed to neurodegeneration\(^{7,13,18}\). We reported that long-term addition of NitroMemantine was more effective than equimolar memantine\(^{18,19}\). Here, we show that NitroMemantine YQW-036 (10\(\mu \)M) spared physiologic synaptic activity to a greater degree than memantine (Fig. 4a–c). Additionally, NitroMemantine spared long-term potentiation (LTP) (Fig. 4d,e), representing augmentation of synaptic currents in response to repeated synaptic inputs, which is thought to be an electrical correlate of learning and memory. Also, similar to memantine\(^{34}\), the Morris water maze, a neurobehavioral test for spatial learning and memory, was not affected by neuroprotective doses of NitroMemantine (Fig. 4f)\(^{18,19,35}\).

**Lack of histological apoptotic damage after NitroMemantine treatment.** Another well-known concern over NMDAR antagonists is their propensity to cause histological damage in certain regions of the brain. For example, high-affinity NMDAR antagonists like MK-801 cause neuronal apoptosis, particularly in the developing rodent brain\(^{36,37}\). However, we found that neither memantine nor NitroMemantine induced neuronal apoptosis in the developing cerebrocortex at clinically-relevant dosage (Supplementary Fig. 3).

**Histological protection and neurobehavioral improvement with NitroMemantine after cerebral ischemia.** Next, we tested the ability of the lead NitroMemantine drug YQW-036 vs. memantine to offer neuroprotection using a rat model of focal cerebral ischemia consisting of transient middle cerebral artery occlusion/reperfusion (tMCAO/R), a model we and others have detailed previously\(^{34,38–40}\). Note we purposely chose a very severe model of cerebrovascular disease such that these animals died in less than two days if not treated; hence, to allow comparison, treated and untreated animals were assessed both behaviorally and histologically one day after stroke. Initially, we tested a full dose-response of drug concentration and time of delivery after insult in order to obtain a therapeutic window post stroke. To obtain significant neuroprotection, we found that we could delay treatment for up to two (but not three) hours after occlusion using the maximal feasible doses (MFDs). Hence, for the present experiments, we used the previously-determined MFD for memantine as the loading dose (90.3\(\mu \)mol/kg...
or 20 mg/kg\[14,34\], administered intraperitoneal (i.p.) at the time of reperfusion (i.e., 2-h post occlusion). For NitroMemantine, only ~70% of this loading dose was injected (65.8 μmol/kg) due to limits of drug solubility. Thereafter, the standard maintenance dose of 4.63 μmol/kg (1 mg/kg) memantine was administered every 12 h\[14,34\], whereas the dose of NitroMemantine was maintained at 70% (3.29 μmol/kg) of the memantine maintenance dose. Both drugs afforded a significant degree of histological protection after focal ischemia (Fig. 5a). Importantly, however, only NitroMemantine produced improvement in functional neurobehavioral tests affecting motor performance, even though the NitroMemantine MFD
was lower than the memantine MFD (Fig. 5b). (Note: physiological parameters, including cranial and rectal temperatures, blood pressure, and metabolic panel, were not significantly affected by the loading dose of memantine or NitroMemantine (Supplementary Table 1)).

Next, in order to permit direct comparison, we tested equimolar concentrations of memantine, NitroMemantine, and its degradation product, memantine-OH, using the MFD of NitroMemantine. We observed that memantine and memantine-OH afforded no significant protection at this dosage, whereas NitroMemantine offered significant benefit on histological analysis (Fig. 5c). Taken together, these findings are consistent with the notion that NitroMemantine offers a superior outcome over memantine for
focal cerebrovascular insults and that this added benefit may be attributable to targeted delivery of the nitro group, affording improved allosteric regulation of the NMDAR.

Discussion

In the present study, we describe the mechanism of action of NitroMemantine, which provides dual-site, hypoxia-regulated antagonism at the NMDAR (Fig. 5d). The features of NitroMemantine that may confer benefit in ischemic neurons are several fold: 1. Voltage-dependent blockade of excessively open, predominantly extrasynaptic NMDAR channels; 2. Targeted-delivery of the nitro group to NMDARs by the memantine scaffold; and 3. Allosteric regulation of channel S-nitrosylation by hypoxia. Targeting of the nitro group likely occurs because open-channel blockers spend an increased proportion of their time near the channel mouth, thereby increasing the statistical odds of the nitro group reacting with vicinal cysteine residues. NitroMemantine thus modulates the biophysical parameter of “gain” of channel activity by providing two allosteric “volume controls” on the NMDAR, represented by memantine action in the channel and S-nitrosylation outside of it. In this manner, excessive extrasynaptic NMDAR activity can be more effectively downregulated by NitroMemantine than by memantine alone.

How S-nitrosylation of the channel occurs precisely is unclear. Alkyl nitrates such as NitroMemantine do not nitrosate directly, nor will they spontaneously release NO. However, they will form thionitrates in reaction with thiols that may rearrange to form nitrosating sulfenyl nitrites. In addition, the cysteine network in the receptor may facilitate the reductive chemistry that is required. Ultimately, since the site of action of the nitro group is external to the voltage field of the channel, the redox contribution
to NMDAR antagonism does not decrease as the neuron depolarizes\textsuperscript{20,22,28}. Thus, NitroMemantine can downregulate excessive NMDAR activity at a point when memantine alone would lose effectiveness.

It might be expected that the nitro group would be targeted to the NMDAR only during periods of open-channel block by the amino adamantane moiety, i.e., in the presence of agonist. Interestingly, however, we observed a redox-mediated effect of NitroMemantine even when drug was added for a prolonged period in between applications of NMDA agonist. These results are understandable based on the known physical chemistry of amino adamantanes, which have a very high lipid-to-water partition coefficient (see Supplementary Information in ref. 35 and citations therein). Our observed decrease in water solubility of NitroMemantine over memantine shows that lipophilicity is increased even further when the nitro group is added. Hence, amino adamantane nitrates appear to remain in the lipid membrane like a reservoir, poised to enter the channel as soon as it opens and then also initiate the redox effect\textsuperscript{29}. We can see that YQW-036 has not entered the channel prior to NMDA application because of the similar rise time of agonist-induced currents before and after antagonist application (Fig. 2c, inset).

If the amino adamantane nitrate were already in the channel prior to NMDA application (i.e., trapped in the closed channel), it would have slowly come out immediately upon agonist application, producing a slower rise time of NMDA-evoked current\textsuperscript{10,28}. Of further note, when a high concentration of YQW-036 was used (100\(\mu\)M rather than 1 to 10\(\mu\)M), the lipophilic effect of the drug was further magnified, as evident in slow washout of a component of the inhibitory effect upon repeated agonist applications (Fig. 2f). Nonetheless, the fact that the prolonged effect of YQW-036 was largely abrogated by prior addition of MTSEA or mutation of redox-active cysteines in the NMDAR indicates that this component of the drug's inhibitory action cannot be attributed solely to increased lipophilicity. Rather, the major component of the prolonged inhibitory effect of YQW-036 is best explained by interaction at the redox site(s) on the NMDAR because it was prevented by both chemical and molecular interventions at the cysteine residues that underlie redox modulation of the receptor\textsuperscript{20}. Moreover, the finding that mutation of the principal binding site of the amino adamantane moiety in the channel (GluN1(N616R)) largely abrogated the prolonged inhibitory effect of YQW-036 (Fig. 2g) is consistent with the notion that the memantine-like action of the drug serves to target the nitro group to the receptor. We cannot rule out the additional possibility that S-nitrosylation by NitroMemantine also increases the receptor's susceptibility to channel block via the adamantane moiety. Moreover, the lipophilic properties of the amino adamantane nitrates should be beneficial clinically in that they increase the concentration of drug permeating the blood-brain-barrier; in fact, due to their lipophilicity, amino adamantanes have been reported to be concentrated at least 20-fold in brain over plasma levels (see citations in ref. 35).

We had previously published evidence that memantine does not accumulate in synaptic NMDAR-associated channels due, at least in part, to its relatively fast off-rate; hence, memantine does not adversely affect the NMDAR-mediated component of excitatory postsynaptic currents (EPSCs), NMDAR-dependent induction of LTP, or behavioral tests such as the Morris water maze\textsuperscript{10,23,32}. The fact that memantine mostly spares synaptic/phasic activity while blocking extrasynaptic/tonically-active NMDARs is thought to underlie its clinical tolerability and reasonable clinical efficacy in human clinical trials\textsuperscript{11–13}. Therefore, our finding that NitroMemantine spares even more synaptic activity while antagonizing extrasynaptic activity to an even greater degree than memantine may account for the new drug's increased efficacy and bodes well for its clinical tolerability in human testing\textsuperscript{18}. Additionally, hypoxic potentiating of receptor inhibition, as seen with NO-based compounds\textsuperscript{22}, is a particularly desirable feature in ischemia. Thus, hypoxia-regulated, allosterically-targeted NMDAR antagonists, although of low affinity, may hold promise for cerebrovascular and other neurodegenerative disorders\textsuperscript{18,19}.

**Methods**

**Vertebrate Animals.** All protocols for use of vertebrate animals were approved by the Sanford-Burnham-Prebys Medical Discovery Institute IACUC and all experiments followed ARAC guidelines. Other methods and any associated references are found in the online version of the paper.

**Chemistry.** We synthesized adamantane nitrates using published reactions. Synthetic schemes and procedures are described in the Supplementary Methods.

**Oocyte recordings of NMDAR-mediated currents under two-electrode voltage clamp.**

Two-electrode voltage clamp recordings at \(-60\) or \(-70\,\text{mV}\) were made on oocytes in frog Ringer's solution two to seven days after injection of NMDAR subunits. Recordings were performed with an Oocyte Clamp OC-725b amplifier (Warner Instrument Corporation, Hamden, CT) using MacLab version 3.5 software (AD Instruments, Milford, MA) at room temperature. Current-injecting electrodes had a resistance of 0.5–1 M\(\Omega\) and voltage-sensing electrodes had a resistance of 1–4 M\(\Omega\). Both electrodes were filled with 3 M KCl. A solution containing 90 mM NaCl, 1 mM KCl, 10 mM HEPES, 1.5 mM BaCl\(_2\), and 10–100\(\mu\)M glycine, pH 7.5 was used to continuously superfuse the oocytes. Barium, rather than calcium, was used as the divalent cation in order to minimize secondary activation of Ca\(^{2+}\)-activated Cl\(^-\) current\textsuperscript{43}. In some experiments, 1.2 mM MgCl\(_2\) was added to the bath solution. Drugs were dissolved in frog Ringer's solution and applied by superfusion at a 2 ml/min flow rate. In some cases, to achieve relatively rapid solution exchange, we used an array of pipettes similar to the "sewer pipe" system used in patch-clamp recording\textsuperscript{44}. Perfusion artifacts were digitally removed from the traces.
Rat cerebrocortical cultures, hippocampal autapse preparation, and recordings of NMDAR-mediated currents under whole-cell clamp. Established methods were used to prepare primary rat cerebrocortical cultures and hippocampal autaptic cultures. Briefly, for rat cortical cultures, cerebrocortices were dissected from embryonic day 16–17 (E16-17) Sprague-Dawley rats. After dissociation, cells were plated on poly-L-lysine-coated dishes in DMEM plus Ham's F12 and 10% heat-inactivated iron-supplemented calf serum. Cultures were incubated at 37°C in a humidified atmosphere of 5% CO₂/95% air for at least three weeks prior to use to insure that their full repertoire of microislands. The microislands were prepared by plating a single-cell suspension of astrocytes on collagen (62.5 μg/ml)/poly-d-lysine (50 μg/ml) microdots on agarose-coated glass coverslips. For cortical cultures, whole-cell recordings were generally performed on neurons after superfusion with 1 μM tetrodotoxin (TTX) to eliminate spontaneous activity in the cultures. For autaptic cultures, whole-cell recordings were obtained from single neurons growing on micro-islands of one or more astrocytes. Recordings were performed at room temperature on cultures 14–26 days in vitro (DIV) with a patch-clamp amplifier (Axopatch 200B or MultiClamp 700A Molecular Devices, Union City, CA). Cultured neurons were superfused at a rate of 2 ml/min with HEPES-buffered external solution (in mM): NaCl, 146; KCl, 2.5; CaCl₂, 2; HEPES, 10; n-glucose, 20; pH 7.4 (NaOH adjusted), 300–310 mOsM. Borosilicate glass capillaries (GC150F-10, Warner Instruments) were used to pull patch pipettes using a micropipette puller (P87, Sutter Instruments, Novato, CA); open tip resistances were 2–7 MΩ with internal solution (in mM): CsCl, 140; NaCl, 4; CaCl₂, 0.5; HEPES, 10; Na-GTP, 0.5; Mg-ATP, 2; EGTA, 5; pH 7.33 (CsOH adjusted); 315 mOsM. Some experiments used a Cs-glutamate based intracellular solution (in mM): Cs-glutamate, 117; NaCl, 9; HEPES, 10; and MgCl₂, 2; EGTA, 10; pH 7.2 (NaOH adjusted). NMDAR-mediated currents were recorded in the absence of extracellular magnesium and with 10–20 μM glycine. Drugs were administered by a fast valve-controlled perfusion system (Lee Company, Essex, CT). Unless otherwise noted, all antagonists were purchased from Tocris Bioscience (Ellisville, MO). Data were acquired and analyzed as filtered and digitized electrical signals using PClamp v.10 software (Axon Instruments, Union City, CA). Data were displayed and analyzed using the statistical software package Origin 7 (OriginLab Corporation, Northampton, MA).

Site-directed mutagenesis of NMDAR subunits. Mutant NMDAR subunits were prepared using the Chameleon™ double-stranded site-directed mutagenesis kit (Stratagene) according to the manufacturer's instructions. The entire coding region was sequenced to verify the mutation.

Water maze neurobehavioral testing. Adult male spontaneously hypertensive rats (SHR) were treated with either PBS or NitroMemantine (65.8 μmol/kg loading dose, i.p., followed by a 3.29 μmol/kg maintenance dose every 12 h). Each group comprised of five rats (n = 5). Treatment for both groups commenced 48 h prior to the first day of testing. Both the treatment and water-maze testing were conducted in a blinded fashion. The water maze consisted of a circular pool 150 cm in diameter and 85 cm deep. The pool was filled to cover a moveable platform, black in color, by 1 cm of water. The water was made opaque via the addition of black paint and maintained at room temperature (20–23°C) for the duration of the five days of testing. A white pool with black water allowed the video camera to successfully track the white rats with maximum contrast. On day 1, the rats were placed in the pool with no platform for 60 s of acclimation. Days 2 through 5 were used for testing. Starting on day 2 and continuing to day 5, rats were trained for 24 total trials (six trials/day) to locate and reach the submerged platform. The platform was kept in the same location for all trials in each session (day), but changed from session to session in a pre-determined order, yielding four unique locations in all. In addition, there were four possible release locations (the four cardinal compass directions at the pool's perimeter). The six trials per session/day for each animal were performed in pairs from different locations, and all animals were tested before proceeding to another pair of trials. Furthermore, the order of drop locations was constant for all rats, but, like the platform, had a pseudo-random order that changed from session to session. Each water-maze testing session was conducted in a continuous manner, without any major time gaps between individual trials or rounds of trial pairs. The maximum allowed time for the rat to successfully reach the platform was 120 s. If the animal did not reach the platform in that time, it was manually guided and given a time of 120 s. Between the two trials, the rat stayed on the platform for a minimum of 5 s (this time period excluded in determining the duration of the test).

Assessment of rat hippocampal LTP by field recordings. Adult rats (275–300 g) were sacrificed by decapitation. Brains were rapidly removed from the skull and placed in cold artificial cerebrospinal fluid (ACSF), in mM: NaCl 116; KCl 5.37; NaHPO₄ 1.02; NaHCO₃ 26.19; CaCl₂ 3.2; MgSO₄ 0.8; n-glucose 10, pH 7.4, saturated with bubbled 95% O₂/5% CO₂, at 3°C. Hippocampi were sliced at 40-μm thickness by a manual tissue chopper (Stoelting). Slices used were from the middle third of the hippocampus, oriented in a plane perpendicular to the septotemporal axis. Slices were transferred in cold ACSF to a flow-through interface chamber and superfused at 33.5°C. ACSF and the air interface were saturated with 95% O₂/5% CO₂ bubbled gas. After a 30-min incubation, the fluid was exchanged for fresh.
Extracellular field excitatory postsynaptic potentials (EPSPs) were recorded in the stratum radiatum of the CA1 region of the hippocampus after stimulation of the CA3 Schaffer collaterals according to our previously published protocols. Recordings were performed with glass microelectrodes filled with ACSF (resistance 1–2 MΩ); bipolar tungsten electrodes (Fred Haer) were used for stimulation. Responses were monitored with an AC amplifier (AM Systems). Recording electrodes were placed in the stratum radiatum at an approximately 100 μm depth under the surface and 1000 μm from the stimulating electrode. Field EPSPs were evoked and an input/output curve generated to determine the stimulus intensity required to induce a half-maximal response. Subsequent stimuli were delivered at this intensity. Paired pulse stimuli were delivered at interstimulus intervals from 6 to 200 ms, and for each interval, the degree of paired-pulse inhibition or facilitation calculated. Slope values of EPSPs were used in the paired-pulse testing paradigm. Only one electrode placement was made per slice to prevent injury to the slice. For 10–20 min, baseline responses were recorded every 30 s. After a period of observing a stable baseline, tetanic stimulation was applied to the slice (100 Hz burst for 1 s) and applied every 30 s for 60–90 min. Percent change in EPSP slope after tetanus was compared to pretetanus baseline. A repeated measures ANOVA was used to compare slopes from the different groups.

Assessment of S-nitrosylation of NMDARs by biotin switch assay. Analysis of S-nitrosylation of NMDA receptors in rat brain was performed by the biotin switch assay, as previously described. Free thiols in tissue lysates were blocked with methyl-methanethiosulfonate. Proteins were then precipitated with acetone and resuspended in HEN buffer (250 mM HEPES, pH 7.4, 1 mM EDTA, 0.1 mM neocuproine) plus 1% sodium dodecyl sulfate. Ascorbate was used to selectively reduce nitrosothiols in order to reform free thiol groups, which were subsequently biotinylated using 1 mM biotin-HPDP (Pierce, Rockford, IL). Parallel reactions were performed without ascorbate as a control to ensure specificity of the biotinylated bands. Biotinylated proteins were captured on streptavidin-agarose beads and analyzed by immunoblotting.

Assessment of cerebrocortical apoptosis after memantine and NitroMemantine treatment. Seven-day-old rats were injected i.p. with vehicle, MK-801, memantine or NitroMemantine and the brains examined 24 h later by TUNEL (terminal deoxynucleotidyl transferase–mediated dUTP nick-end labeling) to detect apoptotic cells. Quantification was performed using the optical dissector and fractionator method (Cruz-Orive and Weibel, 1990). Briefly, a high-aperture objective and a counting frame (0.05 mm by 0.05 mm, dissector height 0.07 mm) were used to visualize and count neurons. Unbiased samplings were performed by randomly selecting 8 to 10 viewing fields within the counting frame at different focal levels using the optical dissector method. The density of normal neurons was determined by counting neurons in 70-μm-thick sections stained with a Nissl stain (methylene blue, azure II). Counting was performed in a blinded manner.

Treatment and histological evaluation of transient middle cerebral artery occlusion with reperfusion (tMCAO/R). Because of their known propensity to stroke, similar to human patients with hypertension, we used spontaneous hypertensive rats (SHR, Harlan) to induce tMCAO/R with the intraluminal suture method. Male 200–300 g SHR were anesthetized with 3% isoflurane in 30% oxygen/70% nitrous oxide using an anesthetic vaporizer and flowmeter. Body temperature was maintained at 37 °C with a homeothermic temperature system. A laser Doppler monitor was used to monitor relative cerebral blood flow (rCBF) during the surgical procedure and recovery. rCBF measurements were made immediately after anesthesia, after occlusion of the MCA, just before, and immediately after withdrawal of the suture to initiate reperfusion. To initiate a stroke, a midline incision was made to expose the right common carotid, external carotid, and internal carotid arteries. The occipital artery branches of the external carotid artery were isolated and along with the terminal lingual and maxillary artery branches coagulated with an electrocautery unit. The internal carotid artery was isolated and carefully separated from the adjacent vagus nerve. The pterygopalatine artery was ligated close to its origin, two loosely tied sutures placed around the external carotid artery stump, and a microaneurysm clip applied to the external carotid artery near its bifurcation with the internal carotid artery. A small puncture opening was made in the external carotid artery, a monofilament (intraluminal suture) inserted through the opening, and the sutures tightened around the lumen containing the filament. The microaneurysm clip was removed from the external carotid artery and the monofilament gently advanced from the lumen of the external carotid artery into the internal carotid artery for a distance of ~19 to 20 mm beyond the bifurcation of the common carotid artery until the blood flow dropped (≥80% reduction by rCBF measurement). The suture around the external carotid artery stump was tightened to prevent bleeding. After 2 h, sutures were removed, the filament withdrawn and the incision sutured removed, with rCBF recovering at least 75% at reperfusion. Just prior to reperfusion, rats were administered memantine, NitroMemantine, or memantine-OH via i.p. injection in saline vehicle or an equivalent volume of vehicle alone. In initial experiments, the loading dose for each drug was 20 mg/kg, corresponding to 90.3 μmol/kg for memantine and 65.8 μmol/kg for NitroMemantine YQW-036 (the ~30% lower dose of NitroMemantine was necessary due to its lower solubility in aqueous solution). Maintenance doses (4.63 μmol/kg of memantine and 3.29 μmol/kg of memantine nitrate) were loaded at 10 h post-surgery and daily thereafter.
kg of NitroMemantine, equivalent to 1 mg/kg or each) were administered 12 h after the loading dose. As demonstrated previously, this dose of memantine produces a biologically effective, neuroprotective concentration of 5–10 μM at the mouth of the NMDAR-associated ion channel. In subsequent experiments, equimolar memantine, NitroMemantine YQW-036, or memantine-OH was used using the lower NitroMemantine dose described above. The rodents were sacrificed 24-h post occlusion, and the size of brain infarct was evaluated histologically by 2,3,5-triphenyl-2H-tetrazolium chloride (TTC) staining.

**Behavioral assessment for neurological impairment after stroke.** Each adult animal underwent a neurologic evaluation immediately after filament removal and again 1 day after reperfusion (prior to sacrifice). Each animal was assigned an objective behavioral score of 0–4: 0 representing no observable neurological deficit; 1 failure to extend the left forepaw; 2 circling to the left; 3 falling to the left; 4 cannot walk spontaneously. The scores obtained 24-h post stroke were averaged for each time point of each treatment group and presented as the neurological score.

**Statistical analyses.** Values for the electrophysiological and histological experiments are presented as mean ± s.e.m. To test for statistical differences between groups, we used a Student’s t-test (two-tailed) for two-way comparisons and an ANOVA with post hoc testing for multiple comparisons. For behavioral testing, non-parametric tests (Mann-Whitney-U test) assessed the significance of the differences under the various conditions. A value of *P* < 0.05 was considered statistically significant.

**References**

1. Lo, E. H. 2013 Thomas Willis Award Lecture: Causation and collaboration for stroke research. *Stroke* **45**, 305–308 (2014).
2. Simon, P. F., Swan, J. H., Griffiths, T. & Meldrum, B. S. Blockade of N-methyl-D-aspartate receptors may protect against ischemic damage in the brain. *Science* **266**, 850–852 (1984).
3. Chen, H. et al. Oxidative stress in ischemic brain damage: mechanisms of cell death and potential molecular targets for neuroprotection. *Antioxid. Redox. Signal.* **14**, 1505–1517 (2011).
4. Dmíngui, L., Iadeoela, C. & Moskowitz, M. A. Pathobiology of ischaemic stroke: an integrated view. *Trends Neurosci.* **22**, 391–397 (1999).
5. Kemp, J. A. & McKernan, R. M. NMDA receptor pathways as drug targets. *Nat. Neurosci.* **5** Suppl. 1039–1042 (2002).
6. Tymanski, M. Emerging mechanisms of disrupted cellular signaling in brain ischemia. *Nat. Neurosci.* **14**, 1369–1373 (2011).
7. Hardingham, G. E. & Bading, H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. *Nat. Rev. Neurol.* **11**, 682–696 (2010).
8. Parsons, M. P. & Raymond, L. A. Extrasynaptic NMDA receptor involvement in central nervous system disorders. *Neuron* **82**, 279–293 (2014).
9. Rogawski, M. A. & Wenk, G. L. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer’s disease. *CNS Drug Rev.* **9**, 275–308 (2003).
10. Chen, H. S. & Lipton, S. A. Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells: uncompetitive antagonism. *J. Physiol.* **499** (Pt 1), 27–46 (1997).
11. Lipton, S. A. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. *Nat. Rev. Drug Discov.* **16**, 55–63 (2013).
12. Talantova, M. et al. Abeta induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. *Proc. Natl. Acad. Sci. USA* **110**, E2518–2521 (2013).
13. Wang, Y. et al. The pharmacology of aminoadamantane nitrates. *Curr. Alzheimer Res.* **3**, 201–204 (2006).
14. Choi, Y. B. et al. Molecular basis of NMDA receptor-coupled ion channel modulation by S-nitrosylation. *Nat. Neurosci.* **3**, 15–21 (2000).
15. Lipton, S. A. & Stamler, J. S. Actions of redox-related congeners of nitric oxide at the NMDA receptor. *Neuropharmacology* **33**, 1229–1233 (1994).
16. Takahashi, H. et al. Hypoxia enhances S-nitrosylation-mediated NMDA receptor inhibition via a thiol oxygen sensor motif. *Neuron* **53**, 53–64 (2007).
17. Chen, H. S. & Lipton, S. A. Pharmacological implications of two distinct mechanisms of interaction of memantine with N-methyl-D-aspartate-gated channels. *J. Pharmacol. Exp. Ther.* **314**, 961–971 (2005).
18. Blanpied, T. A., Clarke, R. J. R. & Johnson, J. W. Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. *J. Neurosci.* **25**, 3312–3322 (2005).
19. Silver, I. A. & Erecinska, M. Intracellular and extracellular changes of [Ca²⁺] in hypoxia and ischemia in rat brain in vivo. *J. Gen. Physiol.* **95**, 837–866 (1990).
20. Williams, L. P., Kuner, T., Seeburg, P. H. & Sakmann, B. Differential contribution of the NR1- and NR2A-subunits to the selectivity filter of recombinant NMDA receptor channels. *J. Physiol.* **491** (Pt 3), 779–797 (1996).
21. Lipton, S. A. et al. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. *Nature* **364**, 626–632 (1993).
22. Lipton, S. A. et al. Cysteine regulation of protein function—as exemplified by NMDA-receptor modulation. *Trends Neurosci.* **25**, 474–480 (2002).
23. Blanpied, T. A., Bocockman, F. A., Atzenman, E. & Johnson, J. W. Trapping channel block of NMDA-activated responses by amantadine and memantine. *J. Neurophysiol.* **77**, 309–323 (1997).
30. Choi, Y., Chen, H. V. & Lipton, S. A. Three pairs of cysteine residues mediate both redox and zn2+ modulation of the nmda receptor. J. Neurosci. 21, 392–400 (2001).
31. Kotermanski, S. E., Wood, J. T. & Johnson, J. W. Memantine binding to a superficial site on NMDA receptors contributes to partial trapping. J. Physiol. 587, 4589–4604 (2009).
32. Chen, H. S. & Lipton, S. A. The chemical biology of clinically tolerated NMDA receptor antagonists. J. Neurochem. 97, 1611–1626 (2006).
33. Parsons, C. G., Stoffler, A. & Daniyas, W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse. Neuropharmacology 53, 699–723 (2007).
34. Chen, H. S. et al. Neuroprotective concentrations of the N-methyl-D-aspartate open-channel blocker memantine are effective without cytoplastic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation. Neuroscience 86, 1121–1132 (1998).
35. Okamoto, S. et al. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat. Med. 15, 1407–1413 (2009).
36. Ikonomidou, C. et al. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 283, 70–74 (1999).
37. Olney, J. W. et al. Drug-induced apoptotic neurodegeneration in the developing brain. Brain Pathol. 12, 488–498 (2002).
38. Gu, Z. et al. A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J. Neurosci. 25, 6401–6408 (2005).
39. Gu, Z. et al. S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science 297, 1186–1190 (2002).
40. Wang, Y. F. et al. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat. Med. 4, 228–231 (1998).
41. Lipton, S. A. Turning down, but not off. Nature 428, 473 (2004).
42. Ischiropoulos, H. et al. Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. Arch. Biochem. Biophys. 298, 431–437 (1992).
43. Leonard, J. P. & Kelso, S. R. Apparent desensitization of NMDA responses in Xenopus oocytes involves calcium-dependent chloride current. Neuron 4, 53–60 (1990).
44. Vylicky, L. Jr, Benveniste, M. & Mayer, M. L. Modulation of N-methyl-D-aspartic acid receptor desensitization by glycine in mouse cultured hippocampal neurons. J. Physiol. 428, 313–331 (1990).
45. Bekkers, J. M. & Stevens, C. F. Excitatory and inhibitory autaptic currents in isolated hippocampal neurons maintained in cell culture. Proc. Natl. Acad. Sci. USA 88, 7834–7838 (1991).
46. Segal, M. M. Epileptiform activity in microcultures containing one excitatory hippocampal neuron. J. Neurophysiol. 65, 761–770 (1991).
47. Segal, M. M. & Furshpan, E. J. Epileptiform activity in microcultures containing small numbers of hippocampal neurons. J. Neurophysiol. 64, 1390–1399 (1990).
48. Jaffrey, S. R. & Snyder, S. H. The biotin switch method for the detection of S-nitrosylated proteins. Sci. STKE 2001, pl1 (2001).
49. Uehara, T. et al. S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration. Nature 441, 513–517 (2006).
50. Bederson, J. B. et al. Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. Stroke 17, 1304–1308 (1986).
51. Mackensen, G. B. et al. Neuroprotection from delayed postischemic administration of a metalloporphyrin catalytic antioxidant. J. Neurosci. 21, 4582–4592 (2001).

Acknowledgements
We thank Mark Washburn for performing preliminary experiments on early derivatives of the NitroMemantine series of drugs, Jonathan Stamler for original contribution to the idea of therapeutic allosteric regulation, design of this compound class, and help in writing the manuscript, Greg Went for help with drug development, and Traci Fang Newmeyer and Ravi Agarwal for excellent technical support. This work was supported in part by NIH grants P01 HD29587, R01 EY05477, R21 NS080799 and P30 NS076411, by Department of Defense (Army) grant W81XWH-13-0053 (to S.A.L.), by an American Heart Association Postdoctoral Fellowship 09POST2120061 (to P.X.), and by a Corporate Sponsored Research Agreement from Adamas Pharmaceuticals, Inc.

Author Contributions
S.A.L. designed and supervised all experiments and prepared the manuscript. Y.W. and J.W.L. performed chemical synthesis of aminoadamantane nitrates, analysis of the structure-activity relationship, and hit-to-lead optimization. H.T., P.X., M.T., T. T, J.P.-C., K.B. and D.Z. performed or analyzed electrophysiological experiments, J.C. and S.S. performed the surgery for the animal model of cerebral ischemia with assistance of E.H. S.R.M. and N.N. helped analyze data, performed statistical analysis, prepared figures, and assisted in experiments. S.A.L. and S.R.M. wrote the manuscript, and all coauthors participated in editing the manuscript.

Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare that S.A.L. is the inventor on world-wide patents for the use of memantine and NitroMemantine for neurodegenerative disorders; Y.W. and J.W.L. are also named inventors on patents for NitroMemantine. Per Harvard University guidelines, S.A.L. participates in a royalty-sharing agreement with his former institution Boston Children’s Hospital/ Harvard Medical School, which licensed the drug memantine (Namenda®) to Forest Laboratories/
Actavis. Additionally, S.A.L. and J.W.L. are scientific founders of Adamas Pharmaceuticals, Inc., which has developed second-generation formulations of memantine with Forest/Actavis.

**How to cite this article:** Takahashi, H. *et al.* Pharmacologically targeted NMDA receptor antagonism by NitroMemantine for cerebrovascular disease. *Sci. Rep.* 5, 14781; doi: 10.1038/srep14781 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/)
Corrigendum: Pharmacologically targeted NMDA receptor antagonism by NitroMemantine for cerebrovascular disease

Hiroto Takahashi, Peng Xia, Jiankun Cui, Maria Talantova, Karthik Bodhinathan, Wenjun Li, Sofiyan Saleem, Emily A. Holland, Gary Tong, Juan Piña-Crespo, Dongxian Zhang, Nobuki Nakaniishi, James W. Larrick, Scott R. McKercher, Tomohiro Nakamura, Yuqiang Wang & Stuart A. Lipton

Scientific Reports 5:14781; doi: 10.1038/srep14781; published online 19 October 2015; updated on 12 February 2016

Sofiyan Saleem was omitted from the author list in the original version of this Article. This has been corrected in the PDF and HTML versions of the Article.

The Author Contributions section now reads:

S.A.L. designed and supervised all experiments and prepared the manuscript. Y.W. and J.W.L. performed chemical synthesis of amino adamantane nitrates, analysis of the structure-activity relationship, and hit-to-lead optimization. H.T., P.X., M.T., T.T., J.P.-C., K.B. and D.Z. performed or analyzed electrophysiological experiments. J.C. and S.S. performed the surgery for the animal model of cerebral ischemia with assistance of W.L. T.N. performed the pharmacodynamic assay showing S-nitrosylation of the NMDA receptor with assistance of E.H. S.R.M. and N.N. helped analyze data, performed statistical analysis, prepared figures, and assisted in experiments. S.A.L. and S.R.M. wrote the manuscript, and all coauthors participated in editing the manuscript.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/